Present and future of drug therapy in hypertension: an overview

Josep Redon1, Rafael Carmena2

  • 1INCLIVA Research Institute, University of Valencia, Valencia, Spain.

Blood Pressure
|March 6, 2024
PubMed

Insights

High blood pressure (HBP) management is crucial due to its high mortality. New antihypertensive drugs offer improved efficacy, reduced side effects, and organ protection, enhancing patient outcomes.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Internal Medicine

Background:

  • High blood pressure (HBP) is a primary cause of mortality and disability, with increasing prevalence.
  • Effective diagnosis and treatment of HBP are essential for preventing complications.
  • Pharmacological treatment remains the cornerstone of hypertension management.

Purpose of the Study:

  • To review the current landscape of antihypertensive drug classes.
  • To highlight recent advancements in antihypertensive therapies.
  • To discuss novel drugs offering organ protection and improved compliance.

Main Methods:

  • Review of current antihypertensive drug classes and their mechanisms.
  • Analysis of recently introduced antihypertensive agents.
  • Exploration of novel administration routes and pharmacogenomic approaches.

Main Results:

  • Existing drugs target blood pressure regulation and hypertension-induced organ damage.
  • Newer antihypertensive drugs provide additional protection against organ damage and metabolic disorders.
  • Emerging strategies include drugs for specific indications, pharmacogenomic approaches, and alternative administration routes like subcutaneous injection.

Conclusions:

  • A summary of the key characteristics of various antihypertensive drug classes is presented.
  • Recent advances focus on enhanced efficacy, reduced adverse effects, and multi-faceted organ protection.
  • Future directions include personalized medicine and improved drug delivery systems for better patient compliance.

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
43
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
690
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K